Evidence map›Paper›PMID 33165542›Full record

ArticleAesthetic surgery journal2021

Granzyme B Is a Biomarker for Suspicion of Malignant Seromas Around Breast Implants.

Marshall E Kadin, John Morgan, Haiying Xu, Caroline Glicksman, David Sieber, William P Adams, Pat McGuire, Mark W Clemens, Archana Thakur, Lawrence G Lum

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Aesthetic surgery journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Marshall E Kadinpathology and laboratory medicine (research), Brown University Alpert Medical School, Providence, RI, USA.
John Morgandirector of the Research Core Facility, Roger Williams Medical Center, Providence, RI, USA.
Haiying XuRoger Williams Medical Center, Providence, RI, USA.
Caroline GlicksmanHackensack Meridian School of Medicine, Seton Hall, NJ, USA.
David Sieber
William P AdamsDepartment of Plastic Surgery, University of Texas Southwestern Medical School, Dallas, TX, USA.
Pat McGuireParkcrest Plastic Surgery, St Louis, MO, USA.
Mark W ClemensDepartment of Plastic Surgery, MD Anderson Cancer Center, Houston, TX, USA.
Archana ThakurUniversity of Virginia Cancer Center, Charlottesville, VA, USA.
Lawrence G LumUniversity of Virginia Cancer Center, Charlottesville, VA, USA.
Providence College · USBrown University · USThe University of Texas MD Anderson Cancer Center · USThe University of Texas Southwestern Medical Center · USUniversity of Virginia · USUniversity of Virginia Cancer Center

Funding

Women's Oncology Program - WONP30CA044579 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Jay William FOX · 1987 to 2026
$72.1M
Targeting Neuroblastoma with armed T cellsR01CA182526 · NCI · WAYNE STATE UNIVERSITY · PI CHEUNG, NAI-KONG V, LUM, LAWRENCE G · 2014 to 2019
$3.9M
NCI NIH HHS P30 CA044579NCI NIH HHS R01 CA182526
6 · The paper itself

Abstract

backgroundGranzyme B (GrB) is a serine protease secreted, along with pore-forming perforin, by cytotoxic lymphocytes to mediate apoptosis in target cells. GrB has been detected in tumor cells associated with systemic and breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) but its potential use for detection of early BIA-ALCL has not been fully investigated.

objectivesPrompted by the increased incidence of BIA-ALCL, the aim of this study was to assess GrB as a new biomarker to detect early disease in malignant seromas and to better understand the nature of the neoplastic cell.

methodsA Human XL Cytokine Discovery Magnetic Luminex 45-plex Fixed Panel Performance Assay was used to compare cytokine levels in cell culture supernatants of BIA-ALCL and other T-cell lymphomas, as well as malignant and benign seromas surrounding breast implants. Immunohistochemistry was employed to localize GrB to cells in seromas and capsular infiltrates.

resultsDifferences in GrB concentrations between malignant and benign seromas were significant (P < 0.001). GrB was found in and around apoptotic tumor cells, suggesting that the protease may be involved in tumor cell death.

conclusionsGrB is a useful marker for early detection of malignant seromas and to identify tumor cells in seromas and capsular infiltrates. Because there is an overlap between the lowest concentrations of soluble GrB in malignant seromas and the highest concentrations of GrB in benign seromas, it is recommended that GrB be used only as part of a panel of biomarkers for the screening and early detection of BIA-ALCL. LEVEL OF EVIDENCE: 5:

Indexed as

Breast ImplantationBreast ImplantsBreast NeoplasmsLymphoma, Large-Cell, AnaplasticBiomarkersFemaleGranzymesHumansSeromaBiomarkersGranzymes

Identifiers

PMID33165542
PMCPMC8842673
OpenAlexW3104234334

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.